Arch Biopartners Inc. (ARCH.V)
TSXV · CAD · Healthcare · Biotechnology
CA$0.85 (-1.16%) as of
Key statistics
- Market cap
- 57.74M
- EPS (TTM)
- -0.0500
- Dividend yield
- 0.00%
- 52-week range
- 0.3900 – 1.4500
- Beta
- 1.80
- Profit margin
- 0.00%
- Volume
- 1.00k
About Arch Biopartners Inc.
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Toronto, ON, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.